MA31516B1 - Modification de la production de glycoprotéine dans des plantes - Google Patents

Modification de la production de glycoprotéine dans des plantes

Info

Publication number
MA31516B1
MA31516B1 MA32504A MA32504A MA31516B1 MA 31516 B1 MA31516 B1 MA 31516B1 MA 32504 A MA32504 A MA 32504A MA 32504 A MA32504 A MA 32504A MA 31516 B1 MA31516 B1 MA 31516B1
Authority
MA
Morocco
Prior art keywords
plant
nucleotide sequence
protein
interest
gnt1
Prior art date
Application number
MA32504A
Other languages
Arabic (ar)
English (en)
Inventor
Aoust Marc-Andre D
Estelle Marquet-Blouin
Muriel Bardor
Carole Burel
Loic Faye
Patrice Lerouge
Louis-Philippe Vezina
Véronique Gomord
Stéphanie Aquin
Christophe Rihouey
Thomas Paccalet
Christophe Sourrouille
Original Assignee
Medicago Inc
Centre Nat Rech Scient
Univ Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc, Centre Nat Rech Scient, Univ Rouen filed Critical Medicago Inc
Publication of MA31516B1 publication Critical patent/MA31516B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8245—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Cultivation Of Plants (AREA)

Abstract

L'invention porte sur un procédé de synthèse d'une protéine d'intérêt de profil de n-glycosylation modifié dans une plante, une partie de la plante ou une cellule végétale. Le procédé comprend la co-expression dans une plante d'une première séquence nucléotidique codant pour une protéine hybride (gnt1-gait) comprenant un domaine cts de la n-acétylglucosaminyl transférase (gnt1) fusionné à un domaine catalytique de la bêta-1,4-galactosyltransférase (gait), la première séquence nucléotidique étant fonctionnellement liée à une première région régulatrice active dans la plante; et la co-expression d'une seconde séquence nucléotidique pour coder pour la protéine d'intérêt, la seconde séquence nucléotidique étant fonctionnellement liée à une seconde région régulatrice qui est active dans la plante. Les première et seconde séquences nucléotidiques sont co-exprimées pour synthétiser une protéine d'intérêt comprenant des glycanes de n-glycosylation modifié dans la plante, une partie de la plante ou la cellule végétale.
MA32504A 2007-06-15 2010-01-12 Modification de la production de glycoprotéine dans des plantes MA31516B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94434407P 2007-06-15 2007-06-15
PCT/CA2008/001139 WO2008151440A1 (fr) 2007-06-15 2008-06-13 Modification de la production de glycoprotéine dans des plantes

Publications (1)

Publication Number Publication Date
MA31516B1 true MA31516B1 (fr) 2010-07-01

Family

ID=40129187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32504A MA31516B1 (fr) 2007-06-15 2010-01-12 Modification de la production de glycoprotéine dans des plantes

Country Status (24)

Country Link
US (1) US20110008837A1 (fr)
EP (1) EP2155880B1 (fr)
JP (1) JP5783720B2 (fr)
KR (2) KR20130075787A (fr)
CN (3) CN103382487A (fr)
AU (1) AU2008261527C1 (fr)
BR (1) BRPI0812538B1 (fr)
CA (2) CA2795379A1 (fr)
DK (1) DK2155880T3 (fr)
EG (1) EG26600A (fr)
ES (1) ES2624776T3 (fr)
HU (1) HUE031698T2 (fr)
IL (1) IL202568A (fr)
MA (1) MA31516B1 (fr)
MX (1) MX2009013665A (fr)
NZ (2) NZ581944A (fr)
PL (1) PL2155880T3 (fr)
PT (1) PT2155880T (fr)
RU (2) RU2499053C2 (fr)
SG (1) SG185249A1 (fr)
SI (1) SI2155880T1 (fr)
TN (1) TN2009000512A1 (fr)
WO (1) WO2008151440A1 (fr)
ZA (1) ZA201000207B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (fr) 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
MX2010007962A (es) 2007-11-27 2010-11-10 Medicago Inc Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina.
US8771703B2 (en) 2008-07-08 2014-07-08 Medicago Inc. Soluble recombinant influenza antigens
MX370690B (es) 2008-07-18 2019-12-19 Medicago Inc Epitopo de inmunizacion de nuevo virus de la influenza.
US10272148B2 (en) 2009-06-24 2019-04-30 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
PL2480658T3 (pl) 2009-09-22 2017-12-29 Medicago Inc. Sposób otrzymywania VLP pochodzenia roślinnego
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
WO2012170678A1 (fr) * 2011-06-07 2012-12-13 Fraunhofer Usa, Inc. Dé-glycosylation in vivo de protéines recombinées par co-expression avec la pngase f
US9181532B2 (en) 2011-07-29 2015-11-10 Icon Genetics Gmbh Production of galactosylated N-glycans in plants
CA2850407C (fr) 2011-09-30 2021-11-23 Medicago Inc. Augmentation du rendement en particules de type viral dans des plantes
KR20130125337A (ko) * 2012-05-08 2013-11-18 경상대학교산학협력단 고-만노오스형 n-글라이칸을 생산하는 식물체 및 이를 이용한 고-만노오스형 n-글라이칸의 생산방법
EP2978848B1 (fr) 2013-03-28 2020-05-06 Medicago Inc. Production de particules de type viral de la grippe dans des plantes
EP3167057B1 (fr) 2014-07-11 2020-03-25 Medicago Inc. Modification de la production de protéines chez les plantes
EA038931B9 (ru) 2014-11-20 2022-02-18 Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений
WO2018098572A1 (fr) 2016-12-01 2018-06-07 Plantform Corporation Plante transgénique à activité fucosyltransférase et xylosyltransférase réduite
EP3682012A1 (fr) * 2017-09-11 2020-07-22 R. J. Reynolds Tobacco Company Méthodes et compositions permettant d'augmenter l'expression de gènes d'intérêt dans une plante par co-expression avec p21
WO2022153973A1 (fr) * 2021-01-15 2022-07-21 デンカ株式会社 Procédé pour déterminer des conditions de culture, et procédé de production d'une protéine souhaitée ou d'un peptide souhaité

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312746A (en) * 1993-01-08 1994-05-17 Life Technologies, Inc. Cloning and expressing restriction endonucleases and modification methylases from caryophanon
GB9524350D0 (en) * 1995-11-29 1996-01-31 Lynxvale Ltd Enhancer-increased gene expression in plants
US5945326A (en) * 1997-03-20 1999-08-31 New England Biolabs, Inc. Method for cloning and producing the Spel restriction endonuclease
EP2264177B1 (fr) * 1998-12-09 2015-09-30 Phyton Holdings, LLC Glycoproteines avec glycosilation humaine
KR100817660B1 (ko) * 1999-10-04 2008-03-27 메디카고 인코포레이티드 외래 유전자의 발현을 조절하는 프로모터
US7125978B1 (en) * 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
BR0014945A (pt) * 1999-10-21 2004-08-31 Monsanto Co Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
NZ518532A (en) * 1999-10-26 2004-02-27 Plant Res Internat B Transgenic plant expressing mammalian beta-1,4- galactosyltransferase
ES2349427T3 (es) * 1999-10-26 2011-01-03 Stichting Dienst Landbouwkundig Onderzoek Glicosilación de tipo mamífero en plantas.
WO2002057468A2 (fr) * 2001-01-19 2002-07-25 The Dow Chemical Company Procede de production secretoire d'une glycoproteine possedant une chaine glucidique de type humain au moyen d'une cellule vegetale
US20030035774A1 (en) 2001-07-18 2003-02-20 Adjei Akwete L. Salt/ion pair medicinal aerosol formulation
HUP0700103A3 (en) * 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP3009507B1 (fr) * 2002-02-13 2020-06-24 Wisconsin Alumini Research Foundation Signal d'incorporation de vecteurs de virus de la grippe
CA2819867A1 (fr) * 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Expression de gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) dans des plantes
CA2923247A1 (fr) * 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimisation du traitement du glycane chez les plantes
US8367374B2 (en) * 2003-01-22 2013-02-05 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
CN1761746B (zh) * 2003-01-22 2016-03-23 罗氏格黎卡特股份公司 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
US7132291B2 (en) * 2003-05-05 2006-11-07 Dow Agro Sciences Llc Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
JP2006212019A (ja) * 2004-04-30 2006-08-17 National Institute Of Agrobiological Sciences 植物を用いたユビキノン−１０の製造方法

Also Published As

Publication number Publication date
JP5783720B2 (ja) 2015-09-24
AU2008261527A8 (en) 2010-01-21
PT2155880T (pt) 2016-11-18
ZA201000207B (en) 2013-09-25
AU2008261527C1 (en) 2014-09-04
US20110008837A1 (en) 2011-01-13
CN104962579A (zh) 2015-10-07
CN103382487A (zh) 2013-11-06
RU2499053C2 (ru) 2013-11-20
RU2013137208A (ru) 2015-02-20
AU2008261527B8 (en) 2014-04-24
EP2155880B1 (fr) 2016-08-10
EP2155880A1 (fr) 2010-02-24
CA2700180C (fr) 2013-01-29
WO2008151440A1 (fr) 2008-12-18
EG26600A (en) 2014-03-23
CA2700180A1 (fr) 2008-12-18
AU2008261527A1 (en) 2008-12-18
BRPI0812538B1 (pt) 2021-03-16
SI2155880T1 (sl) 2017-03-31
IL202568A0 (en) 2011-08-01
JP2010531136A (ja) 2010-09-24
NZ581944A (en) 2012-03-30
TN2009000512A1 (en) 2011-03-31
ES2624776T3 (es) 2017-07-17
WO2008151440A4 (fr) 2009-02-26
KR20130075787A (ko) 2013-07-05
CA2795379A1 (fr) 2008-12-18
NZ598417A (en) 2013-06-28
BRPI0812538A2 (pt) 2014-09-30
DK2155880T3 (en) 2016-12-05
PL2155880T3 (pl) 2017-06-30
WO2008151440A8 (fr) 2010-03-04
AU2008261527B2 (en) 2014-04-10
KR101385050B1 (ko) 2014-05-13
IL202568A (en) 2015-02-26
EP2155880A4 (fr) 2010-08-04
HUE031698T2 (en) 2017-07-28
RU2010101024A (ru) 2011-07-20
MX2009013665A (es) 2010-06-02
CN101918559A (zh) 2010-12-15
SG185249A1 (en) 2012-11-29
KR20100037602A (ko) 2010-04-09

Similar Documents

Publication Publication Date Title
MA31516B1 (fr) Modification de la production de glycoprotéine dans des plantes
Sears et al. Enzyme action in glycoprotein synthesis
Costa et al. Glycosylation: impact, control and improvement during therapeutic protein production
Field et al. Molecular cloning of eukaryotic glycoprotein and glycolipid glycosyltransferases: a survey
Butler et al. The choice of mammalian cell host and possibilities for glycosylation engineering
Hadley et al. Structure and function of nucleotide sugar transporters: Current progress
CN105039473A (zh) 低温和/或低pH值在细胞培养中的使用
WO2007084926A3 (fr) Compositions et méthodes destinées à l'humanisation et à l'optimisation de n-glycanes chez des plantes
CN108350440A (zh) 碱性磷酸酯的制造
Blondeel et al. Supplementing glycosylation: A review of applying nucleotide-sugar precursors to growth medium to affect therapeutic recombinant protein glycoform distributions
JP2004528001A (ja) インビトロにおけるフコシル化組換えグリコペプチド
CN105189761A (zh) 细胞培养方法
Wang et al. Evolution of protein N-glycosylation process in Golgi apparatus which shapes diversity of protein N-glycan structures in plants, animals and fungi
Amann et al. CRISPR/Cas9‐multiplexed editing of Chinese hamster ovary B4Gal‐T1, 2, 3, and 4 Tailors N‐glycan profiles of therapeutics and secreted host cell proteins
Hamilton et al. Progress in yeast glycosylation engineering
Schachter Complex N-glycans: the story of the “yellow brick road”
Ha et al. Understanding of altered N‐glycosylation‐related gene expression in recombinant Chinese hamster ovary cells subjected to elevated ammonium concentration by digital mRNA counting
KR20220122699A (ko) 고도로 시알릴화된 다량체 결합 분자
EP3775251A1 (fr) Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
CA2565410A1 (fr) Methode d'expression de glycoproteines sialylees dans des cellules mammiferes et cellules associees
Czlapinski et al. Synthetic glycobiology: exploits in the Golgi compartment
Villacrés et al. Strategic feeding of NS0 and CHO cell cultures to control glycan profiles and immunogenic epitopes of monoclonal antibodies
Ju et al. Identification of core 1 O-glycan T-synthase from Caenorhabditis elegans
Maï et al. Engineering a human-like glycosylation to produce therapeutic glycoproteins based on 6-linked sialylation in CHO cells
EP3194583B1 (fr) Protéine non fucosylée et procédés associés